Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Clifton R. LaDuane, the Chief Financial Officer and Treasurer of Zevra Therapeutics, Inc. (NASDAQ:ZVRA), recently sold 11,000 shares of the company's common stock. The transaction, which took place on February 13, 2025, was conducted at an average price of $7.861 per share, amounting to a total value of $86,471. The sale comes as the stock trades near $8.07, showing a strong 31% gain over the past year despite the company's volatile trading pattern (Beta 2.0).
Following this sale, LaDuane retains ownership of 51,361 shares in Zevra Therapeutics. The sale was executed under a 10b5-1 trading plan, which was adopted on October 15, 2024. This type of plan allows company insiders to set up a predetermined schedule for selling stocks to avoid concerns about insider trading. According to InvestingPro data, analyst price targets for ZVRA range from $14 to $25, suggesting potential upside despite the company's current unprofitable status.
Zevra Therapeutics, based in Celebration, Florida, operates in the pharmaceutical preparations industry and is listed under the ticker ZVRA on the NASDAQ exchange. With a market capitalization of $430 million, the company maintains a healthy current ratio of 2.88x, though InvestingPro analysis reveals several additional key metrics and insights available to subscribers, including the company's detailed Fair Value assessment and comprehensive financial health score.
In other recent news, Zevra Therapeutics launched MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C (NPC), a rare, progressive, neurodegenerative disorder. The early demand for the treatment has surpassed expectations and is now being shipped to patients. Zevra also reported its third-quarter financial results, revealing a net loss for the quarter, despite the successful launch of MIPLYFFA. However, the company emphasized a strong cash runway extending into 2027, supported by a successful underwritten public offering.
On the other hand, Zevra faced challenges with the launch of OLPRUVA for urea cycle disorders, citing low patient awareness and reimbursement issues. Despite these setbacks, the company remains optimistic about its future, focusing on commercial excellence, pipeline innovation, talent development, and corporate foundation for 2024. Expansion into the EU market for MIPLYFFA is planned, with details expected in early 2024. These are some of the recent developments for Zevra Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.